Unwitting execution drug manufacturer Lundbeck met with human rights organisation Reprieve this week to discuss ways to prevent its anti-epilepsy [drug] being used on America’s death-row…[T]hree months after the company dismissed forcing distributors to sign ‘end user agreements’ to prevent the drug being sold to prisons, chief executive Ulf Wiinberg met with Reprieve to discuss its options. “We have…continued our efforts to solve this problem, on how to make the states stop this misuse of our medicine by writing and contacting the prisons in question,” said Lundbeck representative Mads Kronborg. “Reprieve has highlighted the possibilities in terms of restricting distribution by making it harder for prisons to get the drug while keeping a supply for hospitals to get the drugs to treat patients with severe epilepsy”.